Chronic hepatitis B: Advances in treatment

doi:10.4254/wjh.v6.i5.284

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 5

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6060)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

396

WORD

263

HTML

3377

Figures (1-2)

146

Tables (1-4)

146

Sum=4328

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

942

Download

790

Sum=1732

May 27, 2014 (publication date) through Apr 18, 2024

Times Cited of This Article

Times Cited (25)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. May 27, 2014; 6(5): 284-292
Published online May 27, 2014. doi: 10.4254/wjh.v6.i5.284

Table 3 Cross-resistance data for the most frequent resistant hepatitis B virus variants[43]

HBV variant	LVD	LdT	ETV	ADV	TDF
Wild-type	S	S	S	S	S
M204I/V	R	R	I	S	S
L180M + M204V	R	R	I	S	S
A181T/V	R	R	S	R	I
N236T	S	S	S	R	I
A181T/V + N236T	R	R	S	R	R
L180M + M204V/I ± I179T ± T184G ± S202I/G ± M250I/V	R	R	R	S	S

HBV: Hepatitis B virus; LVD: Lamivudine; LdT: Telbivudine; ETV: Entecavir; ADV: Adefovir; TDF: Tenofovir; S: Sensitive; I: Intermediate/reduced susceptibility; R: Resistant.

Citation: Santantonio TA, Fasano M. Chronic hepatitis B: Advances in treatment. World J Hepatol 2014; 6(5): 284-292
URL: https://www.wjgnet.com/1948-5182/full/v6/i5/284.htm
DOI: https://dx.doi.org/10.4254/wjh.v6.i5.284